endo

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025

July 13, 2025 17:45 ET  | Source: Crinetics Pharmaceuticals, Inc. Data show that PALSONIFY was well tolerated and IGF-1 levels…

5 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

5 months ago